Responsible Party:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT05929079 Â Â
Other Study ID Numbers:
18558J1I-MC-GZBK ( Other Identifier: Master Protocol Eli Lilly and Company )J1I-MC-GSA2 ( Other Identifier: ISA Eli Lilly and Company )2023-503658-11-00 ( Other Identifier: EU Trial Number )
First Posted:
July 3, 2023 Â Â Key Record Dates
Last Update Posted:
August 1, 2023
Last Verified:
July 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Yes
Plan Description:
Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting Materials:
Study ProtocolStatistical Analysis Plan (SAP)Clinical Study Report (CSR)
Time Frame:
a are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access Criteria:
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
URL:
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
